The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2022 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Corporate defaults: The LBO zombies set to stalk the market

A wave of corporate defaults will follow the onset of a vicious global recession as sure as night follows day. But this time, that night will see zombie companies stagger the earth, dragging their uncovenanted leverage multiples behind them. Louise Bowman explains.

Blight of the living dead:


SPEAKING AT A Loan Market Association (LMA) conference in October, Ian Cash, head of Alchemy Partners’ £300 million ($509 million) Special Opportunities Fund, drew an alarmed gasp from an already rather anxious audience by revealing that his five-year expectation is for default rates in the European high yield market to rise to an eye-watering 50%. This prediction is doubly startling considering the figures involved. According to Fitch Ratings, €145 billion B-rated corporate debt is due to refinance in Europe by 2016, €86 billion of which is highly leveraged, pre-crunch LBO debt. In the US, $1.7 trillion high-yield loans were written in 2006 and 2007 alone. Clearly, if default rates range as high as Cash is suggesting, this could become a very big problem indeed. Recovery rates are likely to be much, much lower than historical experience as well.

Headline-grabbing as default predictions such as this are, they conceal the fact that, in this downturn, even some corporates that don’t default could be as much of a concern as those that do. Those companies become zombie companies – firms that are underperforming but refuse to die because the lax documentation that crept into the lending market in the boom years acts as a life support machine to a terminally-ill patient.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree